Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rotavirus outer capsid protein VP4; Rotavirus outer capsid glycoprotein VP7 (VP4 and VP7)
- Target
- VP4 and VP7
- Molecular classification
- Structural viral protein, Glycoprotein (VP7), Protease-sensitive protein (VP4), Viral spike protein (VP4)
01
Overview
Rotavirus is a nonenveloped, triple-layered virus with a double-stranded RNA genome. The outer capsid comprises two key proteins: VP4, the spike protein, mediates cell attachment and penetration, and functions as a hemagglutinin; VP7, the glycoprotein, forms the outer shell and stabilizes the viral particle through Ca^2+^ ions. Both VP4 and VP7 independently elicit neutralizing antibody responses, forming the basis of serotype-specific immunity and vaccine development. VP4 and VP7 genetic diversity is the foundation for G (VP7) and P (VP4) serotyping of rotavirus strains, guiding both surveillance and vaccination strategies.
- Other names
- Rotavirus outer capsid spike proteinviral hemagglutininRotavirus outer shell glycoproteinouter capsid glycoprotein
02
Mechanism of action
Vaccines induce production of neutralizing antibodies targeting VP4 and VP7, blocking viral attachment, penetration, and infection of host cells
03
Biological functions
Cell entry/penetration: VP4 acts as the cell-surface receptor-binding protein and mediates viral attachment and membrane penetrationImmune recognition: Both elicit neutralizing antibodies that contribute to protection against infection; VP7 forms the outer shell and is involved in membrane-displacing assembly and entry stepsViral assembly: VP7 stabilizes the virion's outer layer; VP4 is anchored between layers and participates in structural locking-in-place
04
Disease associations
Infection (Acute gastroenteritis and severe diarrhea, especially in children; major global morbidity)
05
Safety considerations
Vaccine development: antigenic variability among VP4 and VP7 genotypes (G and P types) can potentially reduce coverage or efficacy in certain regions/populationsImmune escape: strain diversity may allow rotavirus to evade vaccine-induced immunity unless properly matched
06
Interacting drugs
Licensed rotavirus vaccines (e.g., live attenuated oral vaccines like Rotarix and RotaTeq target these proteins by inducing neutralizing antibodies)
07
Biomarkers
Presence of VP4/V7-specific neutralizing antibodies in serum is a correlate of protection and response to vaccinationGenotyping of VP4 and VP7 is used for molecular strain characterization and epidemiological surveillance (G and P serotyping)
Beyond the preview
Go deeper on Rotavirus outer capsid protein VP4; Rotavirus outer capsid glycoprotein VP7 (VP4 and VP7).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rotavirus outer capsid protein VP4; Rotavirus outer capsid glycoprotein VP7 (VP4 and VP7).